Obesity Featured Articles

  1. QP Certification Of Investigational Medicinal Products In The EU And UK 10/8/2026

    Personal legal responsibility, post-Brexit certification rules, and a three-part documentation review shape how investigational batches reach patients in the EU and UK, and how sponsors work with their certifying QP.

  2. What Is IRT And How Does It Impact Clinical Trials? 10/8/2026

    Automated randomisation, blind protection, and demand-driven supply handling replace envelope-based methods and paper-based tracking, changing study management from first site activation onward.

  3. What New DIA/Tufts CSDD Data Means For Keeping Patients In Clinical Trials 10/8/2026

    Participant compensation varies widely by region and protocol, and few sponsors calibrate it to patient burden. Payment mechanics and travel cost handling may matter as much as the amounts themselves.

  4. What Is Greenphire Travel For Clinical Trials? 10/8/2026

    Travel logistics can drive patient dropout, and sites often absorb the burden. See how sponsor-funded, coordinator-led travel support for patients and caregivers reframes how retention is protected.

  5. Engaged Patients, Better Data 10/8/2026

    Automatically triggered micropayments tied to completed questionnaires connect patient-reported data collection with payment administration, aiming to support engagement while taking manual payment work off site staff.

  6. Combining Multiple Challenge Models Within A Single Individual 10/8/2026

    Pairing immune challenges in healthy volunteers tests whether pharmacology is consistent across cells, tissue, and systemic responses before patient trials.

  7. What Most Psychiatric Drug Development Programmes Learn Too Late 10/8/2026

    Clinical phase completion doesn’t end uncertainty. Six key questions on brain exposure, pharmacology, therapeutic window, and patient variability can reveal whether the molecule failed, or the mechanism.

  8. How Phase I Trial Ethics Are Changing For Sponsors 10/8/2026

    As early efficacy becomes possible in Phase I studies, hope for benefit must be weighed against limited knowledge, reshaping consent language, risk-benefit review, and protocol design for sponsors and IRBs.

  9. Can We Make Feasibility More Realistic? 10/8/2026

    Drawn from a Clinical Leader Live webinar, this article explores how sponsors can make clinical trial feasibility and enrollment forecasts more realistic by questioning data sources, examining patient and site burdens, challenging protocol assumptions, and looking beyond seemingly convincing answers from historical data and AI.

  10. Your Company Needs Compliance Expertise — But When And From Whom? 10/8/2026

    When should a biotech formalize compliance? Learn how risk, funding, clinical activity, and commercialization shape the right expertise and structure.